About the SPORE
Researchers in the Mayo Clinic Brain Cancer SPORE study the pathogenetic mechanisms that can lead to the development of brain cancer, especially glioma.
Researchers in the Brain Cancer SPORE also develop interventions that can help improve the length and quality of life for patients with brain cancer.
The Mayo Clinic Brain Cancer SPORE focuses on several priorities that were developed by the national Brain Tumor Progress Review Group, including:
- Facilitating the development of novel and less toxic therapeutic agents to treat brain cancer
- Gaining a better understanding of the mechanisms of current agents and therapies and improving treatment outcomes
- Developing teams of like-minded scientists and clinicians (clinical consortia) for immunotherapy
The Mayo Clinic Brain Cancer SPORE promotes a strong collaboration between basic research scientists and clinicians in order to foster meaningful translational studies about glioma and other brain cancer.
The Mayo Clinic Brain Cancer SPORE was first funded by the National Cancer Institute (NCI) in October 2004 with a $10.8 million grant. The grant was successfully renewed in September 2011, when the NCI awarded Mayo Clinic a five-year, $11.4 million grant. The SPORE is currently operating under a no-cost extension.
A SPORE, or Specialized Program of Research Excellence, is a cornerstone of the NCI's efforts to promote collaborative, interdisciplinary translational cancer research. The Mayo Clinic Cancer Center is one of four cancer research centers to receive an NCI SPORE grant for brain cancer research.
The principal investigator within the Mayo Clinic Brain Cancer SPORE is: